KeptStepping down to a lower GLP-1 dose: what the maintenance trial found
- SURMOUNT-MAINTAIN is the first big trial to test a lower 'maintenance' dose of a GLP-1 after weight loss.
- After the maintenance year, people on the full dose were 21.9% below their starting weight, people stepped down to 5 mg were 16.6% below, and people on placebo were 9.9% below.
- Only 8% of the full-dose group and 25% of the 5 mg group regained half or more of what they'd lost, compared with 67% on placebo.
- A lower dose kept much more weight off than stopping, but less than staying on the full dose. The right choice is one for you and your prescriber.
For years the question "can I go down to a lower dose and keep the weight off?" had no trial behind it. In May 2026 that changed, with results from SURMOUNT-MAINTAIN in The Lancet.
What the trial did
Adults with obesity first took tirzepatide (Zepbound) at the highest dose they could tolerate until their weight loss levelled off. Those who had lost at least 5% were then randomly assigned to one of three paths for the maintenance phase: stay on their full dose, step down to 5 mg, or switch to placebo.
What happened
| Maintenance path | Weight vs start of the trial | Regained half or more of the loss |
|---|---|---|
| Stayed on full dose | 21.9% lower | 8% |
| Stepped down to 5 mg | 16.6% lower | 25% |
| Placebo (stopped) | 9.9% lower | 67% |
In plain terms: stepping down kept a lot more weight off than stopping, but about 1 in 4 people on the lower dose still lost half or more of their progress. The authors describe the lower dose as a possible alternative to stopping, and note that individual responses vary.
What it means if you're stepping down
- It's a real option, not a guarantee. Most people on 5 mg kept most of their loss. A meaningful minority didn't, and you can't tell in advance which group you'll be in.
- Watch the trend, not the morning. A weekly average shows slow drift that single weigh-ins hide.
- Decide your line before you step down. For example: "If my weekly average is 3 lb above my step-down weight, I talk to my prescriber."
- Your habits do more of the work now. Less medication usually means more appetite. Protein, strength training and a plan for loud food-noise moments carry more weight than they did on the full dose.
This guide reports a trial. It isn't advice about which dose to take. Any change to your medication is a decision for you and your prescriber.
Common questions
What is a GLP-1 maintenance dose?
It's a lower dose some people move to after reaching their goal, aiming to keep the weight off with less medication. SURMOUNT-MAINTAIN (2026) tested stepping tirzepatide down to 5 mg and found it kept much more weight off than stopping, though less than staying on the full dose.
Will I regain weight on a lower dose?
Some people do. In the trial, 25% of people on 5 mg regained half or more of the weight they had lost over the maintenance period, compared with 8% on the full dose and 67% on placebo.
Is there a maintenance-dose trial for Wegovy?
Not with the same design yet. A related trial, ATTAIN-MAINTAIN, tested switching from injectable semaglutide or tirzepatide to the daily orforglipron pill. See our guide on switching to a GLP-1 pill.
Can Kept tell me what dose to take?
No. Kept doesn't give dosing advice. It shows your weekly average against your step-down weight and helps with the habits that matter more on a lower dose.
Sources
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2026;407:2305-2318. Link